N/A N=182 Reproductive Health Survivorship Care Plan
Breast Cancer · Hot Flashes · Sexual Dysfunction
Primary: Number of Participants With a 50% Decrease in Hot Flash Score — 50; 53 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Phase 2 N=24 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants
N/A N=38 Reproductive Health Survivorship Care Plan Pilot
Breast Cancer · Hot Flashes · Vaginal Dryness
Primary: Hot Flash Frequency — 2.2; 1.4 daily hot flashes
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
N/A N=142 Sexual Function and Wellbeing in Females With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and 1 Year After Surgery. — 0.6; 0.6; 0.6; 0.5 nmol/l — p=0.004
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 3 N=249 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
N/A N=963 Cancer Loyalty Card Study
Ovarian Neoplasms
Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001
N/A N=54 Diet and Physical Activity in Uterine Cancer Survivors
Endometrial Neoplasms
Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=4 Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Phase 3 N=139 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Median Progression-free Survival — 3.2; 4.5 months
Phase 1 N=11 Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal Neoplasms
Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
N/A N=33 HPV DNA Testing Through Mobile Mammography Unit
Cervical Cancer
Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants
Phase 3 N=676 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Human Papillomavirus (HPV) Infection
Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants
Phase 2 N=21 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events
Phase 2 N=18 CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants
N/A N=32 Women's Health Communication Study
Gynecologic Cancer
Primary: Feasibility - Enrollment — 32 Participants
Phase 2 N=26 Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Ovarian Cancer
Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants
N/A N=153 Cervical Cancer Self-Collection for Southeast Asian Immigrant and Refugee Women
Cervical Cancer Screening
Primary: Number of Participants Who Obtain or Self-Report Future Desire for Cervical Cancer Screening — 59; 71 Participants
N/A N=7 Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Epithelial Ovarian Cancer
Primary: Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+ — 8.3 percentage of positively stained cells
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
N/A N=20 Promise Women Project
Human Papilloma Virus · Cervical Cancer
Primary: Number of Women Who Undergo Cervical Cancer Screening. — 20 Participants
Phase 1 N=9 Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 2 N=35 A Study of Nivolumab in Selected Uterine Cancer Patients
Uterine Cancer · Endometrial Carcinoma · Carcinosarcoma
Primary: Progression-Free Survival — 64.7 percentage of patients
Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
N/A N=98 Pilot Study of a Decision Aid Intervention for Family-building After Cancer
Cancer
Primary: Measure Decision Conflict Scale — 52.25; 36.86; 34.55 score on a scale — p=<0.001